0-9
A B C D E F G H I J K L M N O
P Q R S T U V W X Y Z
  • No FAQs found
  • No FAQs found
  • No FAQs found
  • No FAQs found
  • No FAQs found
  • No FAQs found
  • No FAQs found

BRCAvantage™, Comprehensive

Test code(s) 91863

The FAQ information attached by the previously provided link has been retired. The link continues to be available for your historic reference. Current FAQs can be viewed at QuestDiagnostics.com/FAQs.

This is an outdated version of this FAQ. It was effective 10/15/2013 to 06/18/2014.

The current version is available here.

 

Question 1. Who should be offered BRCA1 and BRCA2 mutation testing?

 Generally, men and women with either or both of the following:
 
  • A personal diagnosis of early onset (≤50 years) breast cancer, bilateral breast cancer, and/or ovarian cancer
  • A strong family history of breast and/or ovarian cancer
The National Comprehensive Cancer Network (NCCN) has more detailed criteria for selecting individuals for genetic testing (http://www.nccn.org/professionals/physician_gls/f_guidelines.asp). The guidelines strongly recommend genetic counseling for the patient before ordering this test. The person in the family with the earliest diagnosis of breast and/or ovarian cancer should be tested first whenever possible.
 
For more information or to discuss a family history with a Quest Diagnostics genetic counselor, please call 866-GENE-INFO.

Question 2. Is there a better test for my patient?

If the familial BRCA1 or BRCA2 mutation is known, contact a genetic counselor at 866-GENE-INFO to help you select the most appropriate test. For individuals of Ashkenazi (Eastern European) Jewish heritage, the BRCAvantage, Ashkenazi Jewish Screen (test code 91864) should be performed first.

Question 3. My patient has a positive result. What does this mean?

If your patient tests positive for a deleterious BRCA1 or BRCA2 mutation, he/she is at significantly increased risk for developing breast or ovarian cancer and other related cancers compared to the general population.
 
The NCCN provides up-to-date surveillance and management recommendations for mutation carriers (http://www.nccn.org/professionals/physician_gls/f_guidelines.asp). Referral to an oncology center experienced in treating patients with a BRCA1 or BRCA2 mutation might be considered to discuss options. These options include increased surveillance, chemoprevention, and prophylactic surgery.

Question 4. My patient has a negative result. What does this mean?

  1. Patient previously diagnosed with breast or ovarian cancer.

    No mutation was found in BRCA1 or BRCA2. Your patient’s risk of recurrence or a related new cancer is based on his/her personal and family histories of cancer. In some instances, it may be appropriate to test for other hereditary forms of cancer. Call 866-GENE-INFO to discuss possible further studies.
     
  2. Patient not previously diagnosed with breast or ovarian cancer, but with a family history of breast and/or ovarian cancer
No mutation was found in BRCA1 or BRCA2. Testing an affected family member is recommended for proper risk assessment. Your patient’s risk of cancer is based on his/her personal and family histories of cancer. In some instances, it may be appropriate to test for other hereditary forms of cancer. Call 866-GENE-INFO to discuss possible further studies.

Question 5. My patient has a variant of uncertain significance. What does this mean?

Variants that have not been previously described in the literature or whose significance is unclear based upon all currently available evidence must be correlated with the patient’s clinical presentation and family history. Family studies may be indicated to better understand the clinical significance of this variant. Please call 866-GENE-INFO to discuss with a genetic counselor if you have further questions.
This FAQ is provided for informational purposes only and is not intended as medical advice. A physician’s test selection and interpretation, diagnosis, and patient management decisions should be based on his/her education, clinical expertise, and assessment of the patient.
Document FAQS.120 Revision: 0